Periodic dietary restriction of animal products induces metabolic reprogramming in humans with effects on health

Konstantinos Rouskas; Ozvan Bocher; Alexandros Simistiras; Christina Emmanouil; Panagiotis Mantas; Anargyros Skoulakis; Y.C. Park; Alexandros Dimopoulos; Stavros Glentis; Gabi Kastenmüller; Eleftheria Zeggini; Antigone S. Dimas

doi:10.1101/2024.04.19.24306061

Abstract

Objectives Dietary interventions can be a powerful tool for the prevention and treatment of diseases, but the molecular mechanisms through which diet affects health remain underexplored in humans. Generating robust evidence on the molecular impact of specific dietary patterns in humans will help us harness the power of dietary interventions to improve health.

Methods Here, we compare plasma metabolomic and proteomic profiles between dietary states for a unique group of individuals (N=200) who alternate between omnivory and restriction of animal products for religious reasons. We also contrast findings to a control group of continuously omnivorous individuals (N=211).

Results We find that short-term animal product restriction drives reductions in levels of lipid classes and of branched-chain amino acids, not detected in the control group, and results in metabolic profiles associated with decreased risk for all-cause mortality. We show that 23% of restriction-associated proteins are druggable targets and reveal that pro-longevity hormone FGF21 and seven additional proteins (FOLR2, SUMF2, HAVCR1, PLA2G1B, OXT, HPGDS, SPP1) display the greatest magnitude of change upon restriction. Through Mendelian randomization we demonstrate potentially causal effects of FGF21 and HAVCR1 on risk for type 2 diabetes, of HPGDS on BMI, and of OXT on risk for lacunar stroke.

Conclusions We demonstrate that short-term restriction of animal products results in metabolic reprogramming with mostly positive effects on health and emphasise high-value targets for pharmacological intervention.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded by an ERC grant to Dr Antigone Dimas (FastBio 716998). Dr Ozvan Bocher has received funding from the European Union Horizon 2020 research and innovation programme under Grant Agreement No 101017802 (OPTOMICS).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of BSRC Alexander Fleming gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Manuscript was revised. Supplemental files were updated.

Data Availability

All data produced in the present study are available upon reasonable request to the authors. Proteomics and metabolomics summary statistics are available at Zenodo.

https://zenodo.org/records/10985423